Combination therapy for treatment of brain cancers

A method of treating a subject having brain tumor comprising:

• (a) administering an oncolytic adenovirus to said subject;
• (b) administering an anti-PD-1 antibody to said subject;
• and
• (c) assessing tumor response by measuring tumor size;
• wherein the oncolytic adenovirus is an adenovirus serotype 5 strain, is selectively replication competent in cells defective in the Rb/p16 tumor suppressor pathway, contains a deletion of the 24 nucleotides encoding amino acids 122 to 129 of the adenoviral E1A protein, and/or contains an integrin binding RGD-4C motif;
• and
• wherein the anti-PD-1 antibody is pembrolizumab administered at 200 mg per dose;
• and
• wherein the tumor exhibits reduced growth, no growth, a 10% reduction in tumor mass, a 20% reduction in tumor mass, a 30% reduction in tumor mass, a 40% reduction in tumor mass, a 50% reduction in tumor mass, a 60% reduction in tumor mass, a 70% reduction in tumor mass, an 80% reduction in tumor mass, a 90% reduction in tumor mass, or a 100% reduction in tumor mass following initiation of treatment.